Insight into how patients with prostate cancer interpret and communicate genetic test results: implications for families.
Journal
Journal of community genetics
ISSN: 1868-310X
Titre abrégé: J Community Genet
Pays: Germany
ID NLM: 101551501
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
23
08
2021
accepted:
14
07
2022
pubmed:
23
7
2022
medline:
23
7
2022
entrez:
22
7
2022
Statut:
ppublish
Résumé
Patients with prostate cancer (PCA) are increasingly being offered germline genetic testing for precision therapy, precision management, and clinical trial options. Genetic test results also have implications for family members. How men with PCA perceive their genetic test results and decide whether to share recommendations with family members is not well studied. We interviewed 12 patients who had PCA and genetic testing and received a positive variant/likely positive variant (PV/LPV) (n = 7) or a variant of unknown significance (VUS) (n = 5) result. The semi-structured interview had five sections: genetic testing experience, impact, and interpretation of the test result, deciding whether to communicate test results to family members, impact of communication on family members, and suggestions for genetic counselors and other PCA patients. Interviews were transcribed verbatim and thematic analysis was completed using NVivo software v10. Receipt of PV/LPV or VUS genetic test results was not as emotional as receiving the diagnosis of PCA itself. Seven of the 12 participants chose to share their test results with all relevant family members, 4 chose to share with select family members, and one chose to not disclose to any family members. The majority of family members who were aware of participants' genetic results have not undergone cascade genetic testing or sought cancer screening. Participants with PCA and positive or VUS genetic test results typically share their results with at least immediate family members, but some communication barriers exist. Understanding the best way to provide actionable and relevant information about genetic testing to family members remains a challenge.
Identifiants
pubmed: 35869324
doi: 10.1007/s12687-022-00603-1
pii: 10.1007/s12687-022-00603-1
pmc: PMC9681950
doi:
Types de publication
Journal Article
Langues
eng
Pagination
547-556Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
J Genet Couns. 2012 Apr;21(2):151-61
pubmed: 22134580
Eur J Hum Genet. 2016 Mar;24(3):315-25
pubmed: 26264439
Patient Educ Couns. 2011 Nov;85(2):251-7
pubmed: 21310580
J Clin Oncol. 2006 Feb 1;24(4):700-6
pubmed: 16446344
Cancer Epidemiol Biomarkers Prev. 1999 Apr;8(4 Pt 2):385-92
pubmed: 10207644
Clin Genet. 2005 Jun;67(6):492-502
pubmed: 15857416
J Genet Couns. 2009 Oct;18(5):418-35
pubmed: 19479365
Fam Cancer. 2013 Sep;12(3):537-46
pubmed: 23420550
Fam Cancer. 2016 Oct;15(4):697-706
pubmed: 26897130
Clin Genet. 2004 Nov;66(5):445-51
pubmed: 15479190
JCO Precis Oncol. 2017 May 04;1:
pubmed: 34164591
Am J Mens Health. 2020 May-Jun;14(3):1557988320924932
pubmed: 32449425
Am J Med Genet. 2002 Jan 15;107(2):143-50
pubmed: 11807889
Am J Med Genet C Semin Med Genet. 2003 May 15;119C(1):11-8
pubmed: 12704633
Prostate. 2018 Sep;78(12):879-888
pubmed: 29655297
Sociol Health Illn. 2006 Nov;28(7):969-88
pubmed: 17163862
J Urol. 2020 Dec;204(6):1116-1118
pubmed: 32926644
JAMA Oncol. 2019 Apr 01;5(4):523-528
pubmed: 30730552
J Genet Couns. 2018 Aug;27(4):885-893
pubmed: 29404823
J Natl Compr Canc Netw. 2020 Apr;18(4):380-391
pubmed: 32259785
Prostate. 2020 Apr;80(5):441-450
pubmed: 32027768
J Clin Oncol. 2020 Aug 20;38(24):2798-2811
pubmed: 32516092
N Engl J Med. 2016 Aug 4;375(5):443-53
pubmed: 27433846
Genet Test Mol Biomarkers. 2012 May;16(5):376-82
pubmed: 22085394